Global X U.S. Infrastructure Development ETF PAVE 深 沪
等待开盘 12-18 09:30:00 美东时间
47.945
-0.815
-1.67%
华盛通- 最 高48.935
- 今 开48.74
- 成交量 58.99万股
- 最 低 47.82
- 昨 收 48.76
- 总市值 94.93亿
- 52周最高 49.9378
- 市盈率 静 --
- 换手率 0.30%
- 52周最低 32.5397
- 委 比 -2.06%
- 总股本 1.98亿
- 历史最高 49.9378
- 量 比 0.54
- 振 幅 2.29%
- 历史最低 8.7502
- 每 手 1
- 风险率 3.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多JPMorgan's $1.5 Trillion Security Push Lifts Spotlight On Defense, Critical Minerals And Tech ETFs
JPMorgan's $1.5T SRI and Todd Combs' shift from Berkshire are bringing focus on ETFs tied to long-term U.S. security and resilience themes.
12-09 04:09
Government To Reopen After Historic Shutdown: Federal Services ETFs Mixed As Investors Await Spending Clarity
As the government prepares to end the shutdown, defense, infrastructure, and federal services ETFs are torn between spending hopes and fiscal uncertainty.
11-12 00:08
Apellis Highlights New Phase 3 Data Showing EMPAVELI Sustains Kidney Function And Proteinuria Reduction In Rare Kidney Diseases
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced new data from the open-label period of the Phase 3 VALIANT study that reinforce the robust and sustained efficacy of EMPAVELI® (pegcetacoplan), a C3
10-20 19:13
2025 洛杉矶车展 AUTOMOBILITY LA 登场，汇聚定义未来移动的产业领袖
Cox Automotive 荣誉呈献主舞台：Honda x LA28、Lucid、Pivotal、 ARC Boats 及 PAVE 等重量级嘉宾将分享前...
09-30 00:51
美银重磅报告：AI “卖水人”正在胜出！全球资金下一步可能流向哪里？
美银最新预测显示，受 8 月疲软非农数据影响，美联储今年可能降息 2 次，2026 年再降 3 次，最终利率将降至 3.25% 左右。
09-11 23:15
美银重磅报告：AI “卖水人”正在胜出！全球资金下一步可能流向哪里？
美银最新预测显示，受 8 月疲软非农数据影响，美联储今年可能降息 2 次，2026 年再降 3 次，最终利率将降至 3.25% 左右。
09-11 21:57
Housing Pains? Some ETFs Can Still Build Gains
U.S. construction spending slipped in July, but ETFs reveal a split: homebuilder funds face mortgage headwinds, while infrastructure ETFs may benefit.
09-03 03:42
Where to find high momentum showing a ‘bullish top-down signal’ – Oppenheimer
Oppenheimer analysts believe that the recent underperformance of the momentum factor (NYSEARCA:SPMO), (MTUM) through the broadening of the market is a “bullish top-down signal.” “We see this tactical ...
09-03 01:42
Reported Earlier, Apellis Wins FDA Approval For EMPAVELI To Treat Rare Kidney Diseases C3G And IC-MPGN With 68% Proteinuria Reduction
Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 depositsBroad label includes adults and adolescents with C3G or
07-29 15:32
大摩上调Apellis Pharmaceuticals(APLS.US)目标价至26美元 维持“持有”评级
摩根士丹利分析师Judah Frommer表示，这一评级是基于该公司市场地位及近期财务战略所作出的判断。
07-07 11:58
